Hemochromatosis: Symptoms, Diagnosis, and At-Home Therapeutic Phlebotomy

Hemochromatosis is one of the most common hereditary disorders in people of Northern European descent — affecting roughly 1 in 200 to 1 in 250 people of Irish, Scottish, or Northern European ancestry — yet it often goes undiagnosed for years. The reason: its early symptoms overlap with dozens of other conditions, and many physicians don't screen for iron overload unless they're specifically looking for it. (NIH National Institute of Diabetes and Digestive and Kidney Diseases)

If you or a family member has been diagnosed with hemochromatosis, or you're concerned about chronically elevated ferritin or transferrin saturation levels, this guide explains what hemochromatosis is, how it's confirmed, and why at-home therapeutic phlebotomy is the most convenient path to long-term management.

What is hemochromatosis?

Hemochromatosis is a condition in which the body absorbs more iron from food than it needs. Under normal circumstances, the body absorbs only about 10 percent of dietary iron and regulates what it keeps. In hereditary hemochromatosis — caused primarily by mutations in the HFE gene, particularly C282Y and H63D (MedlinePlus HFE gene reference) — this regulatory mechanism breaks down. The gut absorbs iron indiscriminately, and the excess accumulates in organs: the liver, heart, pancreas, joints, and pituitary gland.

Over years or decades, iron deposits cause progressive organ damage. The liver sustains the heaviest burden — fibrosis, cirrhosis, and in some cases hepatocellular carcinoma. The pancreas develops insulin resistance and eventual diabetes. The joints develop a specific arthropathy, typically beginning in the second and third metacarpophalangeal joints (the knuckles of the index and middle fingers). The heart develops arrhythmias and cardiomyopathy. The pituitary loses function, which can suppress testosterone or estrogen production.

The good news: when caught early — before significant organ damage — hemochromatosis is highly manageable. The treatment is straightforward and effective, and it does not require medication.

Watch: Hemochromatosis explained

Follow us on YouTube for more mobile phlebotomy and lab testing videos.

Symptoms of hemochromatosis

Early-stage hemochromatosis is often completely asymptomatic. When symptoms do appear, they tend to be nonspecific and easily attributed to other causes:

• Fatigue and weakness — the most commonly reported symptom; often dismissed as overwork or poor sleep
• Joint pain — especially in the knuckles, hips, and ankles; often mistaken for early rheumatoid arthritis or osteoarthritis
• Abdominal pain — often in the right upper quadrant as the liver enlarges
• Bronze or grayish skin discoloration — sometimes called "bronze diabetes" when it co-occurs with iron-induced diabetes
• Elevated liver enzymes — an incidental finding on routine blood work that triggers further investigation
• Low libido, erectile dysfunction, or irregular periods — from pituitary iron deposits suppressing sex hormone production
• Heart palpitations or shortness of breath — from cardiac iron accumulation

Because this symptom profile is so broad, hemochromatosis is frequently discovered incidentally — when routine blood work flags a high ferritin, or when a family member is diagnosed and siblings are prompted to test.

How hemochromatosis is diagnosed

Diagnosis requires a combination of blood tests and, in confirmed cases, genetic testing. The standard diagnostic sequence:

Step 1: Transferrin saturation and serum ferritin

A fasting morning blood draw is ideal for the initial screen. Transferrin saturation above 45 percent is the most sensitive early marker. Serum ferritin above 200 ng/mL in women or 300 ng/mL in men warrants follow-up. Note that ferritin is also an acute-phase reactant — it rises with inflammation, alcohol use, fatty liver disease, and other conditions — so an elevated ferritin alone is not diagnostic.

Step 2: HFE genetic testing

If transferrin saturation is elevated, HFE gene mutation testing confirms the diagnosis. The most clinically significant mutations are C282Y homozygosity (the highest-risk genotype, responsible for most clinical hemochromatosis) and compound heterozygosity (C282Y/H63D, which carries lower but real risk). This is a simple blood draw — the same appointment that collects the iron panel can collect the genetic specimen.

Step 3: Liver assessment

In patients with elevated ferritin above 1,000 ng/mL or abnormal liver enzymes, a liver biopsy or MRI liver iron quantification assesses the degree of iron loading and fibrosis. This determines how aggressively treatment needs to proceed.

Treatment: why therapeutic phlebotomy is the primary intervention

There is no medication that corrects hemochromatosis. The treatment is therapeutic phlebotomy — the deliberate, medically supervised removal of blood to reduce the body's iron stores. Each 450–500 mL blood draw removes approximately 200–250 mg of iron, because iron is bound inside hemoglobin in red blood cells.

Watch our short on at-home therapeutic phlebotomy — or visit our YouTube channel for more.

Treatment proceeds in two phases:

Phase 1: Iron depletion

During the initial depletion phase, blood is drawn weekly or every two weeks until ferritin falls to the target range — typically 50 to 100 ng/mL. Depending on baseline iron levels, this phase may require anywhere from 10 to 50 or more sessions. Patients who present with ferritin in the thousands require many months of weekly draws.

Phase 2: Maintenance

Once target ferritin is reached, the frequency drops dramatically. Most patients need only 3 to 6 draws per year to prevent re-accumulation. This maintenance phase continues indefinitely — hemochromatosis does not resolve, but it is completely controllable with consistent treatment.

Patients who comply with phlebotomy treatment and catch the condition before significant organ damage have a normal life expectancy. Organ damage that has already occurred (cirrhosis, established diabetes, established arthropathy) does not reverse with phlebotomy, but progression stops.

Why at-home therapeutic phlebotomy is the best option for most hemochromatosis patients

During the depletion phase, weekly blood draws are demanding on time and logistics. For someone managing a career and family, weekly clinic visits can be genuinely disruptive. At-home therapeutic phlebotomy — where a licensed mobile phlebotomist comes to your home or office — removes that friction entirely.

Beyond convenience, there are clinical advantages to home draws for hemochromatosis patients:

• Consistent scheduling — mobile visits can be locked into a recurring weekly slot, which helps compliance during the long depletion phase
• No wait-room dehydration — patients can hydrate well before and after the draw in their own environment
• Immediate post-draw rest — some patients feel lightheaded after therapeutic draws; recovering at home is safer and more comfortable than driving home from a clinic
• Lab order flexibility — we can draw your therapeutic blood and simultaneously collect a ferritin specimen to track your progress on the same visit

Schedule an at-home therapeutic phlebotomy visit →

Monitoring during treatment

Ferritin and hemoglobin should be checked every 10–12 draws during depletion to verify response and avoid over-depletion (which causes iron-deficiency anemia). An at-home iron panel — ferritin, serum iron, TIBC, and transferrin saturation — can be collected at the same visit as the therapeutic draw, so every appointment produces both treatment and monitoring data.

Once in the maintenance phase, ferritin is checked 1–2 times per year to confirm levels remain in range. Liver enzyme and CBC monitoring continues at least annually.

Is hemochromatosis hereditary? Should family members be tested?

Yes. Hereditary hemochromatosis follows an autosomal recessive pattern. If you carry two copies of the C282Y mutation, each of your children has a 25 percent chance of inheriting the same genotype (if your partner also carries at least one copy, which is common given the frequency of the mutation in people of European descent).

First-degree relatives — parents, siblings, children — of a diagnosed C282Y homozygote should be tested with transferrin saturation, ferritin, and HFE genotyping. Early identification allows intervention before any symptoms or organ damage develop.

Diet and lifestyle with hemochromatosis

Therapeutic phlebotomy does the heavy lifting in hemochromatosis management — but diet reduces the amount of iron your body absorbs between draws, which can slow the pace of iron accumulation during maintenance and reduce how frequently you need treatment.

Foods and substances to limit or avoid:

• Red meat — contains heme iron, the form most efficiently absorbed by the gut. Beef, lamb, and pork are the primary sources. You don't need to eliminate them entirely, but limiting portion size and frequency reduces your iron load.
• Iron-fortified cereals and bread — many processed grain products are fortified with non-heme iron. Check labels, especially on breakfast cereals.
• Vitamin C with iron-rich meals — vitamin C significantly enhances non-heme iron absorption. Taking vitamin C supplements or drinking orange juice with red meat or iron-fortified foods amplifies absorption. Separate them by a few hours.
• Alcohol — alcohol increases intestinal iron absorption and compounds liver damage from iron overload. The combination of excess iron and alcohol accelerates hepatic fibrosis. This is one of the most important lifestyle modifications for patients with any degree of liver involvement.
• Raw shellfish (oysters, clams, mussels) — carry a risk of Vibrio vulnificus infection, which is disproportionately dangerous in patients with iron overload because the bacteria thrive in iron-rich environments. Fully cooked shellfish are safer.

What is generally safe:

• Tea and coffee — both contain polyphenols (tannins) that inhibit non-heme iron absorption (NIH/PubMed Central). Drinking tea or coffee with meals is one of the simplest dietary strategies for hemochromatosis patients.
• Calcium-rich foods — calcium inhibits both heme and non-heme iron absorption. Dairy with meals can modestly reduce iron uptake.
• Fruits, vegetables, and whole grains — fine in normal quantities. Plant-based iron (non-heme) is absorbed at a lower rate than heme iron, and its absorption is further reduced by the presence of phytates and polyphenols in most plant foods.

Diet modification is supportive, not curative — it will not normalize iron levels the way phlebotomy does. But during the maintenance phase, when draws may be spaced months apart, reducing dietary iron absorption helps keep ferritin in range for longer between visits.

Understanding your HFE genetic test results

Most hereditary hemochromatosis is caused by mutations in the HFE gene. When your doctor orders a hemochromatosis genetic test, you'll receive a report describing your genotype. The most clinically significant variants are:

• C282Y homozygous (C282Y/C282Y) — two copies of the C282Y mutation, one inherited from each parent. This is the highest-risk genotype. Approximately 80–85% of clinically diagnosed hereditary hemochromatosis in people of Northern European ancestry is attributable to this genotype. Not everyone with C282Y/C282Y develops clinical disease — penetrance is incomplete — but lab monitoring and clinical follow-up are warranted. (CDC Genomics & Precision Health)
• Compound heterozygous (C282Y/H63D) — one copy of C282Y and one copy of H63D. This genotype carries a lower risk than homozygous C282Y. Most compound heterozygotes do not develop severe iron overload, but a subset — particularly those with other risk factors such as alcohol use, fatty liver disease, or obesity — can develop clinically significant iron accumulation. Monitoring is appropriate.
• H63D homozygous (H63D/H63D) — two copies of H63D. This genotype alone rarely causes significant iron overload and is generally considered a low-penetrance variant. If your ferritin is elevated but you are H63D/H63D, your physician will look for other contributing factors.
• Heterozygous (C282Y or H63D, one copy) — carriers. Carriers absorb slightly more iron than average but rarely develop clinical hemochromatosis. If you're heterozygous and your ferritin is significantly elevated, your physician will investigate secondary causes of iron overload.

Genetic results alone don't determine treatment. The clinical picture — serum ferritin, transferrin saturation, liver enzymes, and symptoms — determines whether and when phlebotomy begins. A C282Y homozygote with a normal ferritin and no symptoms may be monitored; a C282Y homozygote with ferritin above 300 ng/mL and elevated TSAT will typically begin depletion therapy.

Can hemochromatosis be reversed? What to expect long-term

The answer depends on how much organ damage has occurred before treatment begins — which is why early detection matters so much.

What phlebotomy can reverse or prevent:

• Ferritin normalization — reliable and predictable with adequate treatment. Ferritin will fall to target range during the depletion phase and stabilize with maintenance therapy.
• Fatigue and non-specific symptoms — many patients report significant improvement in energy and brain fog once iron levels normalize.
• Early liver fibrosis — mild hepatic fibrosis can improve with iron reduction, particularly in patients who also reduce alcohol intake and manage metabolic risk factors.
• Cardiac function — cardiac complications, including arrhythmias and cardiomyopathy, can improve with aggressive iron depletion when caught before irreversible damage.

What is generally not reversible:

• Established cirrhosis — cirrhotic tissue does not regenerate. Phlebotomy prevents further progression but cannot undo scarring. Cirrhotic patients require ongoing gastroenterology follow-up and hepatocellular carcinoma surveillance.
• Joint arthropathy — the characteristic arthritis of hemochromatosis (typically the index and middle finger knuckles, progressing to larger joints) often does not improve with iron removal. It is the most treatment-resistant complication.
• Established diabetes from pancreatic iron deposition — insulin-dependent diabetes from pancreatic damage usually persists even after iron stores normalize.

Patients diagnosed early — before significant organ damage — can expect a normal life expectancy and good quality of life with ongoing maintenance therapy. The treatment burden in the maintenance phase (a draw every few months) is minimal compared to the alternative of unmanaged disease. At-home therapeutic phlebotomy reduces that burden further by eliminating clinic visits entirely.